25 February 2026
Pure Global: Brazil's MedTech Fast-Track - The Hidden Cost of ANVISA's New Rules
LATAM MedTech Insights
About
This week, we dissect a groundbreaking regulatory shift in Latin America's largest market. Brazil's ANVISA has just unveiled a new, accelerated pathway for high-risk medical devices by recognizing approvals from major global agencies, signaling a major push to attract cutting-edge technology.
But this speed comes with a hidden cost. The new framework also introduces some of the strictest post-market surveillance demands seen in the region. We explore the critical balance between rapid innovation and patient safety, and what this means for MedTech companies eyeing the Brazilian market.
Imagine your company's AI-powered surgical device received FDA approval and can now use a fast-track process for Brazil. You cut your time-to-market by more than a year, but now ANVISA is demanding real-world performance data from Brazilian hospitals to validate its effectiveness locally. How do you leverage the speed of entry without getting buried in this new, intensive compliance burden?
Key Takeaways:
- What is the AREE reliance pathway and which foreign approvals does ANVISA now recognize?
- How does this new rule change the submission strategy for Class III and IV devices in Brazil?
- What are the unwritten expectations for post-market surveillance for fast-tracked devices?
- How can you prepare a real-world data collection plan for the Brazilian market?
- Does this regulatory shift in Brazil signal a wider trend across Latin America?
- What are the biggest compliance risks for companies under this new paradigm?
- How do you manage technical dossier requirements when leveraging a foreign approval?
- What are the key operational costs associated with these new post-market rules?
At Pure Global, we specialize in navigating these complex regulatory shifts. Our combination of local expertise and advanced AI tools helps MedTech and IVD companies streamline market access, from initial strategy to post-market surveillance. We turn regulatory hurdles into opportunities for growth. To learn how we can help you succeed in Brazil and over 30 other markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.
But this speed comes with a hidden cost. The new framework also introduces some of the strictest post-market surveillance demands seen in the region. We explore the critical balance between rapid innovation and patient safety, and what this means for MedTech companies eyeing the Brazilian market.
Imagine your company's AI-powered surgical device received FDA approval and can now use a fast-track process for Brazil. You cut your time-to-market by more than a year, but now ANVISA is demanding real-world performance data from Brazilian hospitals to validate its effectiveness locally. How do you leverage the speed of entry without getting buried in this new, intensive compliance burden?
Key Takeaways:
- What is the AREE reliance pathway and which foreign approvals does ANVISA now recognize?
- How does this new rule change the submission strategy for Class III and IV devices in Brazil?
- What are the unwritten expectations for post-market surveillance for fast-tracked devices?
- How can you prepare a real-world data collection plan for the Brazilian market?
- Does this regulatory shift in Brazil signal a wider trend across Latin America?
- What are the biggest compliance risks for companies under this new paradigm?
- How do you manage technical dossier requirements when leveraging a foreign approval?
- What are the key operational costs associated with these new post-market rules?
At Pure Global, we specialize in navigating these complex regulatory shifts. Our combination of local expertise and advanced AI tools helps MedTech and IVD companies streamline market access, from initial strategy to post-market surveillance. We turn regulatory hurdles into opportunities for growth. To learn how we can help you succeed in Brazil and over 30 other markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.